A causal association between serum mitochondrial-related proteins and the risk of chronic kidney disease

血清线粒体相关蛋白与慢性肾脏病风险之间的因果关系

阅读:1

Abstract

PURPOSE: Previous studies have extensively reported some alterations in mitochondrial-related proteins in patients with chronic kidney disease (CKD). Herein, we used a two-sample Mendelian randomization (MR) to investigate the potential causal relationship between serum mitochondrial-related protein function and CKD. METHODS: The data related to CKD and mitochondrial 2,4-dienoyl CoA reductase 1 were obtained from the genome-wide association studies (GWAS) database; data on other mitochondrial-related proteins were sourced from the IEU (Integrative Epidemiology Unit) database. Inverse-variance weighted (IVW) was used as the main approach for data analysis; weighted median, MR-Egger, and weighted mode methods were used to validate the robustness of the results. MR-Egger regression method was applied to explore the presence of horizontal pleiotropy, while the MR pleiotropy residual sum and outlier (MR-PRESSO) method was used to detect potential outliers. Leave-one-out (LOO) analyses were used to evaluate the presence of predominant instrumental variables (IVs). Cochran's Q test was used to assess heterogeneity among IVs. RESULTS: The IVW approach showed that NADH dehydrogenase (ubiquinone) iron-sulfur protein 4 might be a risk factor for CKD (OR = 0.9825, 95% CI: 0.9659-0.9994, P = 0.0430). In addition, genetically predicted NADH dehydrogenase (ubiquinone) flavoprotein 2, serine tRNA ligase, NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 8, NADH dehydrogenase (ubiquinone) iron-sulfur protein 4, 2,4-Dienoyl CoA Reduction, Diablo Homolog and NAD-dependent protein deacylase sirtuin-5 showed causal association with CKD markers (all P < 0.05). The MR-Egger regression results and MR-PRESSO analysis further confirmed this data. CONCLUSION: These exploratory findings suggest that these genes may play an important role in CKD pathogenesis and represent potential targets for future therapeutic strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。